ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
118
Novel CAR-T therapies from HLB and GC Cell’s US affiliates take spotlight
admin
2022.09.27
117
HLB drug candidate shows longest liver cancer survival duration
admin
2022.09.14
116
Domestic expert positively evaluates rivoceranib’s phase 3 clinical results
admin
2022.09.13
115
HLB’s anticancer drug candidate shows world’s longest survival duration against liver cancer
admin
2022.09.08
114
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression
admin
2022.09.08
113
HLB to supply ₩18.5 billion worth of sterile foam swabs to Abbott
admin
2022.09.06
112
HLB confirms rivoceranib’s safety in phase 1 gastric cancer trial
admin
2022.09.06
111
HLB, “Apply for riboceranib pre-NDA meeting with US FDA”
admin
2022.08.24
110
HLB to release phase 3 results of cancer drug candidate at ESMO 2022
admin
2022.08.24
109
Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
admin
2022.07.25
1
2
3
4
5
6
7
8
9
10
>
>>